Tag results:
T cells
Intestinal Cell News
Interleukin-37 Promotes Colitis-Associated Carcinogenesis via SIGIRR-Mediated Cytotoxic T Cells Dysfunction
[Signal Transduction and Targeted Therapy] Researchers found that IL-37 transgenic mice were highly susceptible to colitis-associated colorectal cancer and suffered from dramatically increased tumor burdens in colon.
Cell Therapy News
Disrupting N-Glycan Expression on Tumor Cells Boosts Chimeric Antigen Receptor T Cell Efficacy against Solid Malignancies
[Science Translational Medicine] The authors showed that multiple carcinomas expressed extracellular N-glycans, whose abundance negatively correlated with CAR T cell killing.
Human Immunology News
Proximity of Immune and Tumor Cells Underlies Response to BRAF/MEK-Targeted Therapies in Metastatic Melanoma Patients
[npj Precision Oncology] In a TCGA-melanoma dataset, tumor cellularity exhibited additive prognostic value in the immune score signature to predict overall survival in patients with early-stage melanoma.
Human Immunology News
Single‐Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment
[Clinical Cancer Research] Researchers used mass cytometry by time-of-flight, flow cytometry, and T cell receptor immunosequencing to conduct simultaneous single-cell analyses of immune cells in the sentinel lymph nodes of melanoma patients.
Immune Regulation News
Interleukin-37 Promotes Colitis-Associated Carcinogenesis via SIGIRR-Mediated Cytotoxic T Cells Dysfunction
[Signal Transduction and Targeted Therapy] Scientists found that IL-37 transgenic mice were highly susceptible to colitis-associated colorectal cancer and suffered from dramatically increased tumor burdens in colon.
Immune Regulation News
Immuno-Engineered Nanodecoys for the Multi-Target Anti-Inflammatory Treatment of Autoimmune Diseases
[Advanced Materials] IFN-γ treatment induced remarkable PD-L1 expression on PD-L1-expressing macrophage membrane (PRM), thereby allowing PRM nanodecoys to bind mPD-1 on CD4+ T cell surfaces or neutralize free sPD-1, which reconstructed the PD-1/PD-L1 inhibitory axis to suppress CD4+ T cell activation and restore immune tolerance.